UCB’s purpose –
Create value for patients,
now and into the future

Full Year 2021
Delivering on UCB’s
Strategy and Commitments

Capital Market Earnings Call
24 February 2022
Disclaimer & safe harbor

This presentation contains forward-looking statements, including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this presentation.

Important factors that could result in such differences include but are not limited to: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this presentation, and do not reflect any potential impacts from the evolving COVID-19 pandemic, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of this pandemic to UCB. UCB expressly disclaims any obligation to update any forward-looking statements in this presentation, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

In the event of any differences between this Presentation and the Annual or Half Year Report, the information included in the Report shall prevail.
<table>
<thead>
<tr>
<th>Agenda Item</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Jean-Christophe Tellier</strong>&lt;br&gt;CEO</td>
<td><strong>OUR PURPOSE</strong>&lt;br&gt;Create value for patients, now and into the future</td>
</tr>
<tr>
<td><strong>Iris Loew-Friedrich</strong>&lt;br&gt;CMO</td>
<td><strong>CLINICAL PIPELINE DELIVERING</strong>&lt;br&gt;“6 out of 6” – Six positive Phase 3 results</td>
</tr>
<tr>
<td><strong>Charl van Zyl</strong>&lt;br&gt;Executive Vice President&lt;br&gt;Neurology Solutions &amp; EU, International Markets</td>
<td><strong>STRONG POSITION IN NEUROLOGY</strong>&lt;br&gt;Leadership position in epilepsy&lt;br&gt;Getting launch ready in generalized myasthenia gravis</td>
</tr>
<tr>
<td><strong>Emmanuel Caeymaex</strong>&lt;br&gt;Executive Vice President&lt;br&gt;Immunology Solutions &amp; Head of U.S.</td>
<td><strong>IMMUNOLOGY</strong>&lt;br&gt;Expanding portfolio in immunology – strong performance with CIMZIA® and EVENITY®, and launch momentum with BIMZELX®</td>
</tr>
<tr>
<td><strong>Sandrine Dufour</strong>&lt;br&gt;CFO</td>
<td><strong>2021 FY PERFORMANCE</strong>&lt;br&gt;Solid financial foundation – ready for the future</td>
</tr>
<tr>
<td><strong>Jean-Christophe Tellier</strong>&lt;br&gt;CEO</td>
<td><strong>CONCLUSION</strong>&lt;br&gt;What the future holds...</td>
</tr>
</tbody>
</table>
Our purpose –
Create value for patients,
now and into the future

Amplify impact for 2025

Jean-Christophe Tellier
CEO
Driving sustained growth while making a positive impact on society

Value for patients
- **>3.7 million** patients
- **31%** reimbursement for all within regulatory labels
- **55%** reimbursement for some but not all within regulatory labels

Value for people at UCB
- **1,359** jobs created
- **81.9%** for our Health, Safety and Wellbeing index

Value for our communities
- **99** projects in the UCB Community Health Fund since 2020

Value the planet by 2030
- **-62%** CO₂ emissions we directly control vs. 2015
- **23%** emissions by our suppliers with Science-Based-Targets alike

Value for shareholders by 2025
- **€ 5.78 billion** revenues
- **€ 1.64 billion** adj. EBITDA
- **16.8** as Sustainalytics rating (low risk)
Guidance 2025

**Leading** in 5 specific patient populations

**Financial guidance** At least €6bn top line

Low- to mid-thirties adj. EBITDA margin

Improved **ESG** rating performance
Our strategic growth path towards 2025

2015-2021

Focus on patients that can benefit most

Delivered...

>3 700 000 patients treated in 2021

Growth in core products. Tracking well towards peak sales

Topline growth 8% CAGR*

Successful launches

BRIVIACT®, NAYZILAM®, EVENITY® and BIMZELX®

Strengthened R&D to deliver new compounds in shorter cycle times

2021/2022: Six positive Phase 3 results out of six studies

BIMZELX® approved in Europe, GB, Japan and Canada

Enhanced financials and strategic flexibility

Net debt/adj. EBITDA FY 2021 0.5x after 1.0x in 2020

Identify & act on potential new opportunities

Acquisitions of RA Pharma, NAYZILAM®, Engage Therapeutics and Handl Therapeutics

Partnership with Roche/Genentech;
2021: Partnership with Novartis
2022: Agreement to acquire Zogenix

Integrate sustainability for business and societal impact

Good and improving ratings: Sustainalytics, ISS ESG, CDP, WDI

* CAGR: 2015-2021
Eight years of strong growth
Continued investment in innovation to deliver growth

**Annual Revenue**

+8% CAGR

- **2013**: €3.1bn
- **2014-2020**: €5.8bn
- **2021**: €5.8bn

**Adjusted EBITDA**

+15% CAGR

- **2013**: €0.5bn (17%)
- **2014-2020**: €1.6bn (28%)
- **2021**: €1.6bn (28%)
# 2021 FY performance | At-a-glance

Sustainable growth, delivering on UCB’s strategy and guidance

<table>
<thead>
<tr>
<th>Revenue</th>
<th>€ 5.78 billion (+10% CER)</th>
<th>Net Sales</th>
<th>€ 5.47 billion (+11% CER)</th>
<th>+8%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underlying Profitability (adj. EBITDA)</td>
<td>€ 1.64 billion (+14%; +21% CER)</td>
<td>or 28% of revenue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Pipeline delivers</td>
<td>Six positive Phase 3 studies, submissions Q3 2022 onwards</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Launch mode...</td>
<td>BIMZELX®</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Psoriasis: launched in EU + UK; approved in Japan, Canada U.S. expected H1 2022</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Psoriatic arthritis &amp; axial spondyloarthritis: in preparation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>External growth opportunity</td>
<td>Neuroinflammation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Generalized Myasthenia Gravis: in preparation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guidance 2022*</td>
<td>Planned acquisition of Zogenix, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Revenue expected: € 5.15 - 5.4 bn</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>adj. EBITDA: 26 - 27%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Excluding planned Zogenix acquisition – to be included upon closing
We are... 

**ENTERING** a transition phase, followed by **accelerated company growth**

**IN A STRONG POSITION** also underlined by six very positive phase 3 study read-outs from our late-stage pipeline

**CONFIDENT** creating value for all stakeholders
Clinical pipeline delivering

“6 out of 6”
Six positive Phase 3 results

Iris Loew-Friedrich
CMO
2021 & 2022: An unprecedented string of six positive Phase 3 read-outs and approvals

Clinical milestones

- 19-NOV21 BIMZELX® in PsA BE OPTIMAL
- 16-DEC21 BIMZELX® in AS BE MOBILE 2
- 18-JAN22 BIMZELX® in nr-axSpA BE MOBILE 1
- 21-JAN22 BIMZELX® in PsA BE COMPLETE
- 4-FEB22 zilucoplan in gMG RAISE

Regulatory milestones

- AUG21: APPROVAL BIMZELX® in EU and GB
- SEP21: APPROVAL VIMPAT® pediatric label extension
- OCT21: APPROVAL BRIVIACT® pediatric label extension
- NOV21: APPROVAL BIMZELX® in Japan
- DEC21: APPROVAL BIMZELX® in Canada
- JAN22: POSITIVE CHMP OPINION BRIVIACT® and VIMPAT® on pediatric use
- FEB22: TODAY

...and more to come in Q3-2022: Submissions for bimekizumab, rozanolixizumab and zilucoplan

Proprietary and Confidential Property of UCB

gMG: generalized Myasthenia Gravis
PsA: Psoriatic arthritis
AS: Axial spondyloarthritis
nr-axSpA: non-radiographic axial spondyloarthritis
CHMP: Committee for Medicinal Products for Human Use
EU: Europe; GB: Great Britain

Inspired by patients. Driven by science.
**Strong clinical development performance**

Unprecedented 6/6 positive Phase 3 read-outs

---

> **3 100**

Global approvals* for core marketed products last two years

> **5 000**

Global approvals** for clinical trial applications

---

**Probability of success** by clinical trial phase and therapeutic area

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>P1 to P2</th>
<th>P2 to P3</th>
<th>P3 to Approval</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology</td>
<td>57.6</td>
<td>32.7</td>
<td>35.5</td>
<td>3.4</td>
</tr>
<tr>
<td>Metabolic / endocrinology</td>
<td>76.2</td>
<td>59.7</td>
<td>51.6</td>
<td>19.6</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>73.3</td>
<td>65.7</td>
<td>62.2</td>
<td>25.5</td>
</tr>
<tr>
<td>CNS</td>
<td>73.2</td>
<td><strong>51.9</strong></td>
<td>51.1</td>
<td>15.0</td>
</tr>
<tr>
<td>Autoimmune / inflammation</td>
<td>69.8</td>
<td><strong>45.7</strong></td>
<td>63.7</td>
<td>15.1</td>
</tr>
<tr>
<td>Genitourinary</td>
<td>68.7</td>
<td>57.1</td>
<td>66.5</td>
<td>21.6</td>
</tr>
<tr>
<td>Infectious disease</td>
<td>70.1</td>
<td>58.3</td>
<td>75.3</td>
<td>25.2</td>
</tr>
<tr>
<td>Ophthalmology</td>
<td>87.1</td>
<td>60.7</td>
<td>74.9</td>
<td>32.6</td>
</tr>
<tr>
<td>Vaccines (infectious disease)</td>
<td>76.8</td>
<td>58.2</td>
<td>85.4</td>
<td>33.4</td>
</tr>
<tr>
<td>Overall</td>
<td>66.4</td>
<td>48.6</td>
<td>59.0</td>
<td>13.8</td>
</tr>
<tr>
<td>Overall (excluding oncology)</td>
<td>73.0</td>
<td>55.7</td>
<td>63.6</td>
<td>20.9</td>
</tr>
</tbody>
</table>

---


*per formulation (BRIVIACT, KEPPRA, VIMPAT, NAYZILAM (US only), NEUPRO, CIMZIA, EVENTY (EU only), BIMZELX; CMC variations, label updates, new indications, first time approvals

**Initial filings, amendments; US – not applicable as FDA does not formally approve INDs or amendments
Bimekizumab in active psoriatic arthritis (PsA)

Translating clinical results into impact on patients’ daily life – as seen through the secondary efficacy endpoint

Minimal Disease Activity (MDA)

Minimal Disease Activity (MDA) is a composite measure of PsA. Achieving MDA has been shown to:

- Improved Health-related quality of life
- Less structural progression
- Being more productive

Bimekizumab helps patients achieve MDA as shown in both BE OPTIMAL and BE COMPLETE which means

- Having control of disease manifestations
- Better quality of life
- Less likely to develop permanent disability
- Less joint surgery/replacement
- More likely to carry on working and maintain an active social life
- Like you, more patients can make the most of their lives

Main symptoms of PsA

- Psoriatic skin lesions
- Enthesitis of superior/inferior patella or lateral epicondylar
- Dactylitis
- Inflammatory arthritis involving PIP/DIP joint distribution
- Plantar fasciitis/Achilles tendon pain
- Tender/swollen sacroiliac pain
- Psoriatic nail lesions
- Scalp psoriasis
- Psoriatic skin lesions

Giannelli, A. A Review for Physician Assistants and Nurse Practitioners on the Considerations for Diagnosing and Treating Psoriatic Arthritis. Rheumatol Ther 6, 5–21 (2019), https://doi.org/10.1007/s40744-018-0133-3. Bimekizumab is an investigational product in PsA and is not approved for this indication by any regulatory authority in the world. Bimekizumab requires additional studies before any conclusions for safety and efficacy can be made.
Rozanolixizumab and zilucoplan in generalized myasthenia gravis

Translating clinical results into improvements on patients’ daily life – as seen through a range of patient reported outcome measures*

**Improvements impacting patients’ lives** mean:
- Better control of symptoms
- Regain ability to move and to talk and re-engage in social activities
- Less fatigue enabling a journey back to normal life
- Improvement in professional and personal life
- Positive impact on emotional well-being

gMG is a chronic disease that is characterized by fluctuating episodes of exacerbations and periods without symptoms.
# UCB late-stage pipeline | Timelines confirmed

**BIMZELX® (bimekizumab; IL-17A&F inhibitor)**

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Filing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psoriasis</td>
<td>✔️</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>✔️</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Axial spondyloarthritis</td>
<td>✔️</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hidradenitis suppurativa</td>
<td>✔️</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ZILUCOPLAN (C5 inhibitor)**

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Filing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generalized myasthenia gravis</td>
<td>✔️</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ROZANOLIXIZUMAB (FcRn inhibitor)**

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Filing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generalized myasthenia gravis</td>
<td>✔️</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immune thrombocytopenia</td>
<td>✔️</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MOG-antibody disease</td>
<td>✔️</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autoimmune encephalitis</td>
<td>✔️</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**DIAPRORILIZUMAB PEGOL (anti-CD40L antibody)**

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Filing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic lupus erythematosus**</td>
<td>✔️</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**STACCATO® ALPRAZOLAM**

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Filing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stereotypical prolonged seizures</td>
<td>✔️</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**BEPRANEMAB (anti-tau antibody)**

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Filing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer’s disease***</td>
<td>✔️</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**UCB0599 (α-syn-misfolding inhibitor)**

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Filing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parkinson’s disease****</td>
<td>✔️</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* ✔️ = Recent Phase 3 positive topline results published

---

*Regulatory approvals are underway in US, Canada, Australia and Switzerland; market authorization in EU, GB, Japan & Canada; under review in the U.S.*

**in partnership with Biogen; ***in partnership with Novartis; Zilucoplan in amyotrophic lateral sclerosis (ALS) by HEALÉY ALS Platform Trial; MOG — myelin oligodendrocyte glycoprotein

---

**Market authorization in EU, GB, Japan & Canada; under review in the U.S.*

**Submission Q3 2022**

**Read-out earlier than expected**

**Submission Q3 2022**

**Submission Q3 2022**

**New indication**

**New indication**

**Submission Q3 2022**

**Submit topline results H1 2024**

**Submit topline results H1 2024**

**Submit topline results H1 2024**

**Submit topline results H2 2022**

**Submit topline results H2 2022**

**Submit topline results H2 2022**

**Submit topline results H2 2024**

**Submit topline results H2 2024**

**Submit topline results H2 2024**

**Submit topline results H1 2024**

**Submit topline results H1 2024**

**Submit topline results H1 2024**

**Submit topline results H1 2025**

**Submit topline results H2 2023**

**Submit topline results H2 2023**
Leadership position in epilepsy

Getting ready to launch in gMG

Charl van Zyl
Executive Vice President
Head of Neurology Solutions & EU – International Markets
Over 20 years of R&D expertise and commercial success

Strong commitment to people living with epilepsy underlined by strong partnerships

Leadership in epilepsy
- >25,000 patients in >250 clinical studies; >10 epilepsy conditions
- Compelling in-market portfolio outgrowing the market

Highlights 2021/22
- >3 million epilepsy patients treated in 2021
- VIMPAT® peak sales ambition of >€1.5 bn achieved
- BRIVIACT® outperforming branded market by ~3x
- BRIVIACT® US approval for children (1 month)
- Phase 3 program: STACCATO® alprazolam
- Proposed acquisition of Zogenix, Inc.

Recognition of our science

Bepranemab: partnership with Roche/Genentech in Alzheimer’s disease

UCB0599: partnership with Novartis in Parkinson’s disease
Paradigm shift from suppression of seizures to disease modification

Evolving from broad to specific populations with advanced understanding of disease biology

TODAY

Suppression of seizures

Drug resistant 30%

Medically controllable 70%

Acute seizure therapy

Autoimmune epilepsy

Dravet syndrome

Lennox-Gastaut syndrome

FUTURE

Focus specific populations

Proposed acquisition of Zogenix, Inc.

- Acquires "possible best in class" treatment option
- Builds on UCB's focus on epilepsy and ambitions to bring even greater value to people living with seizures
- Enhances epilepsy offering and rare diseases priorities
- Contributes to sustainable, long-term company growth

Drug resistant (DR) is not achieving seizure freedom ≥1 year

Semah et al; Is the underlying cause of epilepsy a major prognostic factor for recurrence, Neurology (51) 1256-1262, 1998
Brenner et al; Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy, Epilepsia, 54(6),1028–1035, 2013; www.orpha.net (data on syndromes); www.epilepsydiagnosis.org (ILAE data on classification of seizures)
Unique portfolio comprising two mechanisms of action poised to transform the Myasthenia Gravis landscape

AChR+, acetylcholinesterase receptor positive; FcRn, neonatal Fc receptor; gMG, generalized myasthenia gravis; MOA, mechanism of action, MuSK+, muscle specific kinase positive; zilucoplan and rozanolixizumab are investigational products and are not approved for any indication by any regulatory authority in the world. Zilucoplan and rozanolixizumab require additional studies before any conclusions for safety and efficacy can be made.

Current treatment options

- Many patients not well-controlled
- High level of disease and treatment burden

Dual mechanisms of action approach to address individual needs of patients

AChR+ patients

Zilucoplan
Complement 5 inhibitor to address complement activation

Maintenance therapy

AChR+ / MuSK+ patients

Rozanolixizumab
Anti-FcRn antibody to address pathogenic auto-antibodies

Add-on treatment for exacerbations

Treatment goals:

- Fewer people experience exacerbations
- More symptom free days
Expanding portfolio in immunology

Strong performance with CIMZIA® and EVENITY®, and launch momentum with BIMZELX®

Emmanuel Caeymaex
Executive Vice President
Immunology Solutions & Head of U.S.
CIMZIA® increasing volume outweighed pricing impacts

CIMZIA® +12% volume, reaching 170,000 patients

2021 FY
CIMZIA® Net Sales
€ 1,841 Million
(+2%; +5% CER)

Pricing impacts compensated:
- Germany: TNF Jumbo group; APR21
- US: Medicare Part B; LYO; JUL21

CIMZIA® continues to out-grow the mature TNF segment, thanks to differentiation

- Rheumatology:
  - Growth of patients on-therapy

- Dermatology:
  - Growth of patients on-therapy

Source: IQVIA Source of Business (US immunology patients), 12 months ending November.
PFS = pre-filled syringe; LYO = lyophilized version; Derm = PSO patients; Rheum = RA, PsA, and axSpA patients; Includes both self- and HCP-administered markets
Bimekizumab delivering patient value in a competitive environment

Set to expand across the spectrum of IL-17 mediated diseases

Creating exceptional patient experiences in psoriasis

axSpA: axial spondyloarthritis; HS: hidradenitis suppurativa; PsA: psoriatic arthritis; bimekizumab is an investigational product in PsA, axSpA, and HS, and is not approved for these indications by any regulatory authority in the world. Bimekizumab requires additional studies before any conclusions for safety and efficacy can be made.
Competitive BIMZELX® uptake in first launch markets

Comparison of launch uptake curves since approval date (cumulative doses)

DE Source: Insight Health NPI
UK Sources: BIMZELX® based on HealthNet homecare deliveries to patients. Weekly volume for analogues estimated based on IQVIA Midas monthly. UCB Independent analysis of data to allow adequate comparisons across different dosing schedules.
Laying the foundations for BIMZELX®

In Germany, BIMZELX® is rapidly gaining IL-17 share in new patient starts

BIMZELX® dynamic patient share* in dermatology; within IL-17

*Excluding samples
Source: Estimated treated patients (factorized data from IQVIA Midas) linked to patient insights from Insight Health PIA
U.S. dermatologists recognize the relevance of IL-17F in addition to IL-17A

Dual inhibition of IL-17A and IL-17F perceived to be the most effective source of IL-17 inhibition by US Dermatologists

- IL-17A: 5%
- IL-17RA: 6%
- Dual neutralization of IL-17A and IL-17F: 46%
- Tri-specific IL-17A/F nanobody: 1%
- Don't know: 29%
- IL-17's are equally effective: 13%

Source: Spherix Global Insights: Plaque Psoriasis (US) Q4 2021
Establishing bone builder leadership with EVENITY®

Getting ready to expand

**Reached world-wide**
- > 200,000 patients at high risk of fracture since launch
- 2021 Performance world-wide
  - ~ $600 million in-market sales* +43%

**Source:** Based on data from IQVIA on the bone builder market: Evenity, Forteo, teriparatide biosimilars/generics + Teribone (Japan) + Tymlos (US). (normalized to "Days of Therapy")

**EVENITY® Share of the Bone Builder Market**
- **US**
  - Launched April 2019
  - 46%
- **Japan**
  - Launched March 2019
  - 31%
- **Germany**
  - Launched March 2020
  - 26%

*Refer to Amgen, Astellas
EVENITY® approved in EU (DEC19) and in Switzerland (JUN20)

Thereof net sales in Europe
- €10 million

Demands Action for Patients

**Proprietary and Confidential Property of UCB**
2021 FY Performance

Solid financial foundation - Ready for the future

Sandrine Dufour
CFO
## Strong net sales growth | Strong product portfolio

### 2021 FY Net sales

€ 5 471 million

(8%; +11% CER)

![Epilepsy Sales Pie Chart]

### Epilepsy

- **CIMZIA®**: €1 841 million (29%)
  - Act: +2% 
  - CER: +5%
  - Strong volume growth: +12%, despite adverse pricing, 170 000 patients

- **VIMPAT®**: €1 549 million (29%)
  - Act: +7% 
  - CER: +10%
  - Strong growth in all markets +9% volume, over 800 000 patients, reaching peak sales ambition,

- **KEPPRA®**: €970 million (18%)
  - Act: +23% 
  - CER: +27%
  - Driven by in-market net sales booking for Japan, over 2 million patients (volume -3%)

- **NEUPRO®**: €307 million (6%)
  - Act: -1% 
  - CER: 0%
  - Stable in a competitive market environment, 385 000 patients, volume -1%

- **NAYZILAM®**: €57 million (1%)
  - Act: >100% 
  - CER: >100%
  - Continued successful launch, over 50 000 patients, volume +70%

- **EVENITY®**: €10 million (1%)
  - Act: >100% 
  - CER: >100%
  - Europe, launched March 2020, volume +412%, reached world-wide over 200 000 patients since launch

- **BIMZELX®**: €4 million (1%)
  - Act: -10% 
  - CER: -7%
  - Launched in Germany, UK, Sweden and the Netherlands

- **Established Brands (EB)**: €321 million (6%)
  - Act: -10% 
  - CER: -7%
  - Continued generic erosion

---

**CER** = constant exchange rates

Net sales include €57 million designated hedges reclassified to net sales
## 2021 FY financial highlights

We enter 2022 from a position of strength

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>Actual</th>
<th>CER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td><strong>€ 5 471 Million</strong> +8% (+11% CER)</td>
<td><strong>€ 5 777 million</strong></td>
<td>+8%</td>
</tr>
<tr>
<td></td>
<td>Driven by volume growth</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gross Profit</strong></td>
<td><strong>€ 4 339 million</strong> +9% +12%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gross margin improved from 74.5% to 75.1% due to product mix</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Operating Expense</strong></td>
<td><strong>€ 3 021 million</strong> +4% +5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+10% marketing and selling expenses including digital: CIMZIA® / NAYZILAM® / EVENITY® / BIMZELX® launches + preparations; pre-launch activities in gMG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+4% R&amp;D expenses:</td>
<td>Late-stage pipeline with five Phase 3 assets – Ratio 28% after 29% in 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Higher other operating income</td>
<td>net contribution from Amgen in connection with the commercialization of EVENITY®</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted EBITDA</strong>*</td>
<td><strong>€ 1 641 million</strong> +14% +21%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusted EBITDA/revenue ratio 28% after 27% in 2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Profit</strong></td>
<td><strong>€ 1 058 million</strong> +39% +51%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lower other expenses (€ 34 million after € 122 million in 2020), Tax Rate 14%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Core Earnings per Share</strong></td>
<td><strong>€ 6.49</strong> +21% +26%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based on 189 million weighted average shares outstanding** (2020: 189m)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CER = constant exchange rates

*Earnings before Interest Taxes Depreciation & Amortization. **Total number of shares 194.5 million.
ESG Ratings

- **MSCI**: A
- **ISS ESG**: C+
- **CDP**: B (climate change), B (water security)
- **WDi**: +5% (disclosure score)

16.8 (low risk)
Ending 2021 in a strong financial position

Capital allocation priorities

- Investment in R&D/innovation, maximized by partnerships
- Capital expenditure
- Provide shareholders with steady growing dividend proposal for 2021: €1.30 (gross) +2%
  - Strategic M&A and BD – for sustained long-term growth
    - Planned acquisition of Zogenix, Inc.*
      - Closing expected by end of Q2 2022
      - Total transaction value (incl. CVR) of up to ~US$ 1.9bn / ~€ 1.7bn
      - Financing through a new US$ 800m 5-year term loan (expected maturity date in 2027) and existing cash sources
- Share repurchases solely in context of equity-based long-term incentives

Maintain a strong and flexible balance sheet

Net debt
€ 860 m
after € 1 411m
in 2020

Net debt/
adj. EBITDA 0.5x
after 1.0x
in 2020

* Transaction subject to completion of tender offer (majority of Zogenix shares) and antitrust clearances and other customary closing conditions
CVR: contingent value rights
Financial guidance for 2022 – a transition year

Update expected upon successful closure of the planned Zogenix, Inc. acquisition***

Revenue expected € 5.15 - 5.40bn
Continued core products growth, loss of exclusivity for E KEPPRA® in Japan, for VIMPAT® in the U.S. and the EU plus the U.S. launch of BIMZELX®

Adjusted EBITDA*/ revenue margin expected 26 - 27%
R&D expense at similar absolute level as 2021

Core EPS € 4.80 – 5.30**
Tax rate expected in the “mid-teens”%****

Peak sales guidance

≥ € 2bn By 2024
≥ € 1.5bn achieved in 2021 By 2022
≥ € 600m By 2026

* Earnings before Interest Taxes Depreciation & Amortization,
** Based on 189 million shares outstanding
*** expected by the end of Q2 2022
**** excluding potential tax reforms
Guidance 2025

Leading in 5 specific patient populations

Financial guidance
- At least €6bn top line
- Low- to mid-thirties adj. EBITDA margin

Improved ESG rating performance
Our purpose – Create value for patients, now and into the future

Amplify impact for 2025

Jean-Christophe Tellier
CEO
UCB is…

DELIVERING
Peak sales for core products, new launches, positive results for pipeline assets

ON TRACK
To amplify impact by 2025 | Launching BIMZELX® and in rare diseases

IN GREAT SHAPE
Strong R&D, great partnerships, solid financials and strategic flexibility

CONFIDENT
We have strong growth ahead... and are creating value for all stakeholders
Thank you... your questions, please